September 25, 2018

IN RE: MIMEDX GROUP, INC. SHAREHOLDER DERIVATIVE LITIGATION

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. October 09, 2020

    MiMedx Investors Get Initial OK For Fraud Deal, $3.5M In Fees

    A Georgia federal judge has given preliminary approval to a derivative settlement that would require new controls at MiMedx Group Inc. and pay $3.5 million to plaintiffs' counsel to resolve shareholders' allegations that the biotech company's executives engaged in a yearslong scheme to inflate revenue. 

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!